Connect Biopharma
CNTB · Nasdaq · United States
Share price · CNTB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CNTB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 15 Sep 2026-32.2%
- 14 Sep 2026-15.4%
Nothing announced by CNTB that day or the session before.
- 3 Sep 2026-30.1%
Nothing announced by CNTB that day or the session before.
- 2 Sep 2026+16.9%
Nothing announced by CNTB that day or the session before.
- 13 Aug 2026+9.0%
- 9 Jul 2026+19.8%
Nothing announced by CNTB that day or the session before.
- 7 Jul 2026-6.4%
Nothing announced by CNTB that day or the session before.
- 12 May 2026+14.5%
- 30 Mar 2026-15.9%
- 26 Mar 2026+9.8%
Nothing announced by CNTB that day or the session before.
Share of unusual movement by asset
For each asset, the share of CNTB's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Rademikibartevents and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 14% |
| Other company news (earnings, financing, releases naming no asset) | — | 7% |
| Sessions with no dated event | — | 78% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthma |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (8)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $2.8M | $16M | $27M+ $4.5M short-term inv. | $17M-$16M operating cash flow | report ↗ |
View 7 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0.2M | $15M | $46M+ $0 short-term inv. | $19M-$16M operating cash flow | report ↗ |
| 2025-Q3 | <$0.1M | $11M | $38M+ $17M short-term inv. | $17M-$17M operating cash flow | report ↗ |
| 2025-Q2 | $0.1M | $8.8M | $41M+ $31M short-term inv. | $13M-$13M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $6.6M | $48M+ $36M short-term inv. | $10M-$10.0M operating cash flow | report ↗ |
| 2024-Q3 | $1.2M | $9.0M | $97M | $13M-$13M operating cash flow | report ↗ |
| 2024-Q2 | $24M | $5.3M | $110M | —-$7.7M operating cash flow | report ↗ |
| 2024-Q1 | — | $8.7M | $114M | $8.7M-$0.6M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.1M | $38M | $38M+ $6.0M short-term inv. | $14M-$51M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($4.4M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-30 | LIU JEAN I · director | Award / grant | 8,984 | — | — | Form 4 |
| 2026-09-30 | Xanthopoulos Kleanthis Gabriel · director | Award / grant | 5,000 | — | — | Form 4 |
| 2026-06-30 | LIU JEAN I · director | Award / grant | 6,718 | — | — | Form 4 |
| 2026-06-30 | Xanthopoulos Kleanthis Gabriel · director | Award / grant | 3,738 | — | — | Form 4 |
| 2026-05-29 | Huang James · director | Open-market purchase | 150,000 | $2.48 | $372K | Form 4 |
| 2026-03-31 | LIU JEAN I · director | Award / grant | 5,061 | — | — | Form 4 |
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel · director | Award / grant | 2,816 | — | — | Form 4 |
| 2026-03-31 | Huang James · director | Open-market purchase | 1,160,000 | $3.45 | $4.0M | Form 4 |